Unlikely a disease marker, poly glycine-proline might track therapeutic efficacy in clinical trials.
The largest study yet on neurofilament light chain suggests plasma levels rise with disease and correlate with other signs of neurodegeneration.
Unbiased screen turns up genes expressed in immune cells, both inside and outside the CNS.
Scientists derive a genetic score that predicts the likely age at which a person will develop Alzheimer’s disease.
Daily doses of the antioxidants vitamin E and/or selenium did not reduce incidence of dementia in cognitively normal older men in a randomized, controlled trial.
The toxic Aβ accumulated at postsynapses of a mouse model one month before plaques developed.
A report claims that in the U.K. dementia research grew substantially since 2008, but more gains are needed to find treatments.
Trials enrolling people all at the same Braak stage would need fewer participants to show a drug effect, according to a new analysis.
Route to toxicity converges with RNA binding proteins in membrane-less organelles.
The proposed budget would strike a blow to biomedical research, and science in general.
Tiny infarcts disrupt glymphatic clearance throughout the brain, allowing toxic waste to stick around and inflame surrounding tissue.
In a bizarre twist of cell biology, researchers find proteasomes in the neuronal plasma membrane. They pump signaling peptides into the extracellular space.
Study of disease subtypes boosts case for NfL as predictor of rapidly progressing ALS.
Primary care records from the last two decades show a slight boost in dementia diagnoses, although this may stem from increased recognition of the disease.
Mice carrying a human ApoE4 gene were more susceptible than those carrying ApoE3 to diabetes-related cognitive problems.